135 related articles for article (PubMed ID: 32455662)
1. Clinical Characteristics of Korean Breast Cancer Patients Who Carry Pathogenic Germline Mutations in Both BRCA1 and BRCA2: A Single-Center Experience.
Hur JY; Kim JY; Ahn JS; Im YH; Lee J; Kwon M; Park YH
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32455662
[TBL] [Abstract][Full Text] [Related]
2. Clinical Characteristics and Exploratory Genomic Analyses of Germline BRCA1 or BRCA2 Mutations in Breast Cancer.
Park S; Lee E; Park S; Lee S; Nam SJ; Kim SW; Lee JE; Yu JH; Kim JY; Ahn JS; Im YH; Park WY; Park K; Park YH
Mol Cancer Res; 2020 Sep; 18(9):1315-1325. PubMed ID: 32554602
[TBL] [Abstract][Full Text] [Related]
3. Mutations of TP53 and genes related to homologous recombination repair in breast cancer with germline BRCA1/2 mutations.
Kim J; Jeong K; Jun H; Kim K; Bae JM; Song MG; Yi H; Park S; Woo GU; Lee DW; Kim TY; Lee KH; Im SA
Hum Genomics; 2023 Jan; 17(1):2. PubMed ID: 36604691
[TBL] [Abstract][Full Text] [Related]
4. Predominance of
Pujol P; Yauy K; Coffy A; Duforet-Frebourg N; Gabteni S; Daurès JP; Penault Llorca F; Thomas F; Hughes K; Turnbull C; Galibert V; Rideau C; Corsini C; Collet L; You B; Geneviève D; Philippe N
Cancers (Basel); 2022 Jul; 14(13):. PubMed ID: 35805038
[TBL] [Abstract][Full Text] [Related]
5. Association of gBRCA1/2 mutation locations with ovarian cancer risk in Japanese patients from the CHARLOTTE study.
Yoshihara K; Enomoto T; Aoki D; Watanabe Y; Kigawa J; Takeshima N; Inomata H; Hattori K; Jinushi M; Tsuda H; Sugiyama T
Cancer Sci; 2020 Sep; 111(9):3350-3358. PubMed ID: 32495382
[TBL] [Abstract][Full Text] [Related]
6. Hematologic toxicities of chemotherapy in breast and ovarian cancer patients carrying BRCA1/BRCA2 germline pathogenic variants. A single center experience and review of the literature.
Hu-Heimgartner K; Lang N; Ayme A; Ming C; Combes JD; Chappuis VN; Vazquez C; Friedlaender A; Vuilleumier A; Bodmer A; Viassolo V; Sandoval JL; Chappuis PO; Labidi-Galy SI
Fam Cancer; 2023 Jul; 22(3):283-289. PubMed ID: 37119509
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of Pathogenic Germline
Abe A; Imoto I; Tange S; Nishimura M; Iwasa T
Genes (Basel); 2022 Jun; 13(6):. PubMed ID: 35741847
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: subgroup analyses by germline
Ayoub JP; Wildiers H; Friedlander M; Arun BK; Han HS; Puhalla S; Shparyk Y; Jakobsen EH; Wu M; Bach BA; Feng D; Ratajczak CK; Maag D; Diéras V
Ther Adv Med Oncol; 2021; 13():17588359211059601. PubMed ID: 34917174
[TBL] [Abstract][Full Text] [Related]
9. Endometrial Cancers in
Smith ES; Da Cruz Paula A; Cadoo KA; Abu-Rustum NR; Pei X; Brown DN; Ferrando L; Sebastiao APM; Riaz N; Robson ME; Soslow RA; Reis-Filho JS; Mandelker D; Weigelt B
JCO Precis Oncol; 2019; 3():. PubMed ID: 32914019
[TBL] [Abstract][Full Text] [Related]
10. Characteristics of double heterozygosity for BRCA1 and BRCA2 germline mutations in Korean breast cancer patients.
Noh JM; Choi DH; Nam SJ; Lee JE; Kim JW; Kim SW; Kang E; Lee MH; Ahn SH; Kim KS; Park SK; Haffty BG;
Breast Cancer Res Treat; 2012 Jan; 131(1):217-22. PubMed ID: 21847643
[TBL] [Abstract][Full Text] [Related]
11. Genomic Signatures from Clinical Tumor Sequencing in Patients with Breast Cancer Having Germline BRCA1/2 Mutation.
Kim JW; Kang HE; Choi J; Yun SG; Jung SP; Bae SY; You JY; Choi YJ; Kim YH; Park KH
Cancer Res Treat; 2023 Jan; 55(1):155-166. PubMed ID: 35681111
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy-related agranulocytosis as a predictive factor for germline BRCA1 pathogenic variants in breast cancer patients: a retrospective cohort study.
Lang N; Ayme A; Ming C; Combes JD; Chappuis VN; Friedlaender A; Vuilleumier A; Sandoval JL; Viassolo V; Chappuis PO; Labidi-Galy SI
Swiss Med Wkly; 2023 Mar; 153():40055. PubMed ID: 37011610
[TBL] [Abstract][Full Text] [Related]
13. Incidence and impact of brain metastasis in patients with hereditary BRCA1 or BRCA2 mutated invasive breast cancer.
Garber HR; Raghavendra AS; Lehner M; Qiao W; Gutierrez-Barrera AM; Tripathy D; Arun B; Ibrahim NK
NPJ Breast Cancer; 2022 Apr; 8(1):46. PubMed ID: 35393462
[TBL] [Abstract][Full Text] [Related]
14. Genetic Counselling, BRCA1/2 Status and Clinico-pathologic Characteristics of Patients with Ovarian Cancer before 50 Years of Age.
Cvelbar M; Hocevar M; Novakovic S; Stegel V; Perhavec A; Krajc M
Radiol Oncol; 2017 Jun; 51(2):187-194. PubMed ID: 28740454
[TBL] [Abstract][Full Text] [Related]
15. Awareness and Availability of Routine Germline
Lux MP; Decker T; Runkel ED; Niyazov A; Quek RGW; Marschner N; Harbeck N
Breast Care (Basel); 2022 Feb; 17(1):40-46. PubMed ID: 35350106
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history.
Engel C; Rhiem K; Hahnen E; Loibl S; Weber KE; Seiler S; Zachariae S; Hauke J; Wappenschmidt B; Waha A; Blümcke B; Kiechle M; Meindl A; Niederacher D; Bartram CR; Speiser D; Schlegelberger B; Arnold N; Wieacker P; Leinert E; Gehrig A; Briest S; Kast K; Riess O; Emons G; Weber BHF; Engel J; Schmutzler RK;
BMC Cancer; 2018 Mar; 18(1):265. PubMed ID: 29514593
[TBL] [Abstract][Full Text] [Related]
17. High prevalence and predominance of BRCA1 germline mutations in Pakistani triple-negative breast cancer patients.
Rashid MU; Muhammad N; Bajwa S; Faisal S; Tahseen M; Bermejo JL; Amin A; Loya A; Hamann U
BMC Cancer; 2016 Aug; 16(1):673. PubMed ID: 27553291
[TBL] [Abstract][Full Text] [Related]
18. Follow-up of tissue genomics in BRCA1/2 carriers who underwent prophylactic surgeries.
Kotoula V; Papadopoulou K; Tikas I; Fostira F; Vrettou E; Chrisafi S; Fountzilas E; Koliou GA; Apostolou P; Papazisis K; Zaramboukas T; Asimaki-Vlachopoulou A; Miliaras S; Ananiadis A; Poulios C; Natsiopoulos I; Tsiftsoglou A; Demiri E; Fountzilas G
Breast Cancer; 2021 Nov; 28(6):1367-1382. PubMed ID: 34304347
[TBL] [Abstract][Full Text] [Related]
19. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
Walsh T; Casadei S; Coats KH; Swisher E; Stray SM; Higgins J; Roach KC; Mandell J; Lee MK; Ciernikova S; Foretova L; Soucek P; King MC
JAMA; 2006 Mar; 295(12):1379-88. PubMed ID: 16551709
[TBL] [Abstract][Full Text] [Related]
20. The first Japanese nationwide multicenter study of
Enomoto T; Aoki D; Hattori K; Jinushi M; Kigawa J; Takeshima N; Tsuda H; Watanabe Y; Yoshihara K; Sugiyama T
Int J Gynecol Cancer; 2019 Jul; 29(6):1043-1049. PubMed ID: 31263023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
